ArticleAnnals of surgical oncology2026
Identifying the Optimal Treatment for Patients with Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Multicenter Propensity Score-Weighted Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPortal hypertension restricts the available therapeutic choices for hepatocellular carcinoma (HCC), adversely impacting patients' prognosis. Established guidelines regarding the treatment of patients with clinically significant portal hypertension (CSPH) are still a matter of debate. This study aimed to evaluate the therapeutic outcomes and identify the optimal treatment strategy for such a population. MATERIALS AND
methodsThe Kaplan-Meier method was utilized for survival analyses. The inverse probability of treatment weighting and multivariate Cox regression models were implemented to adjust for confounding covariates. The relationships between prognostic index and observation end points were evaluated using restricted cubic spline curves.
resultsOf the enrolled 3013 patients with HCC with CSPH, 342 (11.4%), 1056 (35.0%) and 1615 (53.6%) underwent ablation, liver resection (LR), and transarterial chemoembolization (TACE), respectively. The preliminary analysis indicated that a substantial level of heterogeneity existed within the entire population, while LR possessed the acceptable short-term safety and rendered a potential trend toward a survival benefit over interventional treatments after adjustment for confounding covariates. After we classified the patients on the basis of tumor burden, the distinct advantages of LR over interventional treatments concerning overall survival and disease-free survival were confirmed, and these advantages were coincident among all subset analyses and personalized treatment allocation analyses.
conclusionsBoth surgical and interventional treatments could offer survival benefits for patients with HCC with CSPH, while LR provided a notable survival advantage in comparison to interventional therapies, even in patients classified as having intermediate or advanced-stage HCC. LR should be prioritized if it is amenable rather than contraindicated.
Indexed as
Identifiers
41240198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.